Details

Autor(en) / Beteiligte

• Lim, Seng Gee
• Phyo, Wah Wah
• Shah, Samir R.
• Win, Khin Maung
• Hamid, Saeed
• Piratvisuth, Teerha
• Tan, Soek Siam
• Dan, Yock Young
• Lee, Yin Mei
• Ahmed, Taufique
• Yang, Wei Lyn
• Chen, Kok Pun
• Kamat, Mrunal
• Wadhawan, Manav
• Madan, Kaushal
• Mehta, Rajiv
• Shukla, Akash
• Dhore, Prashant
• Eapen, Chundamannil E.
• Abraham, Priya
• Tyagi, Satyendra
• Koshy, Abraham
• Bwa, Aung Hlaing
• Jafri, Wasim
• Abid, Shahab
• Arisar, Fakhar Ali Qazi
• Tanwandee, Tewesak
• Yin, Thing Phee
• Tee, Hoi Poh
• Hj Md Said, Rosaida Binti
• Goh, Khean Lee
• Ho, Shiaw Hooi
• Mohamed, Rosmawati
• Abu Bakar, Norasiah

Titel

Findings from a large Asian chronic hepatitis C real‐life study

Ist Teil von

• Journal of viral hepatitis, 2018-12, Vol.25 (12), p.1533-1542

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2018

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Summary There is a paucity of information on chronic hepatitis C (CHC) patients treated with direct antiviral agents (DAAs) in Asia. We invited Asia‐Pacific physicians to collate databases of patients enrolled for CHC treatment, recording baseline clinical, virologic and biochemical characteristics, sustained virologic response at week 12 (SVR12) and virologic failure. SVR12 outcome was based on intention to treat (ITT). Multivariate analysis was used to assess independent risk factors for SVR12 using SPSS version 20. A total of 2171 patients from India (n = 977), Myanmar (n = 552), Pakistan (n = 406), Thailand (n = 139), Singapore (n = 72) and Malaysia (n = 25) were collected. At baseline, mean age was 49 years, 50.2% were males, and 41.8% had cirrhosis. Overall, SVR12 was 89.5% and by genotype (GT) based on ITT and treatment completion, respectively, was 91% and 92% for GT1, 100% and 100% for GT2, 91% and 97% for GT3, 64% and 95% for GT4, 87% and 87% for GT6 and 79% and 91% for GT untested. Patients with cirrhosis had SVR12 of 85% vs 93% for noncirrhosis (P < 0.001) (RR 2.1, 95% CI 1.4‐3.1, P = 0.0002). Patients with GT1 and GT3 treated with sofosbuvir/ribavirin (SR) had 88% and 89% SVR12, respectively, but those GT6 treated with sofosbuvir/ledipasvir (SL) had only 77.6% SVR12. Multivariate analysis showed absence of cirrhosis was associated with higher SVR12 (OR 2.0, 95% CI 1.3‐3.1, P = 0.002). In conclusion, patients with GT1 and GT3 with/without cirrhosis had surprisingly high efficacy using SR, suggesting that Asians may respond better to some DAAs. However, poor GT6 response to SL suggests this regimen is suboptimal for this genotype.